ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

PSTV Plus Therapeutics Inc

1,80
0,00 (0,00%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Plus Therapeutics Inc PSTV NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,00 0,00% 1,80 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
1,80 1,80 1,84 1,80 1,80
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
22.4.202413:00GLOBEPlus Therapeutics Receives $3 Million Award Recommendation..
08.3.202422:30EDGAR2Form S-1/A - General form for registration of securities..
05.3.202422:04EDGAR2Form 8-K - Current report
05.3.202422:01EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27.2.202400:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.2.202400:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.2.202400:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.2.202400:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.2.202400:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.2.202400:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.2.202400:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.2.202400:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.12.202323:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.11.202322:22EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
22.11.202322:08EDGAR2Form S-1 - General form for registration of securities under..
21.11.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
20.11.202313:01EDGAR2Form 8-K - Current report
17.11.202313:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.11.202313:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.11.202313:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.11.202313:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.10.202321:55EDGAR2Form 8-K - Current report
31.10.202321:06EDGAR2Form 8-K - Current report
31.10.202321:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
15.9.202313:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.9.202313:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.9.202313:00GLOBEPlus Therapeutics Receives $1.9 Million Advance Payment from..
08.9.202313:00GLOBEPlus Therapeutics Enters into License Agreement for..
05.9.202313:00GLOBEPlus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a..
30.8.202313:00GLOBEPlus Therapeutics to Present at the H.C. Wainwright 25th..
21.8.202312:05EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14.8.202322:12EDGAR2Form 8-K - Current report
14.8.202322:05GLOBEPlus Therapeutics Reports Second Quarter 2023 Financial..
14.8.202322:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11.8.202312:30GLOBEPlus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at..
09.8.202313:55EDGAR2Form S-1 - General form for registration of securities under..
08.8.202322:05GLOBEPlus Therapeutics to Announce Second Quarter 2023 Financial..
08.8.202317:22GLOBEPlus Therapeutics Announces Key Opinion Leader Roundtable on..
03.8.202313:00GLOBEPlus Therapeutics to Present at the Canaccord Genuity 43rd..
27.7.202322:05GLOBEPlus Therapeutics Strengthens Clinical Program with the..
27.7.202313:00GLOBEPlus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer..
13.7.202313:00GLOBEPlus Therapeutics to Present at the 2nd Annual Targeted..
29.6.202313:00GLOBEPlus Therapeutics Reports Positive Interim Updates from Two..
14.6.202313:00GLOBEPlus Therapeutics to Participate in the 2023 Healthcare..
08.6.202313:00GLOBEPlus Therapeutics Announces Participation at Upcoming SNO..
01.6.202313:00GLOBEPlus Therapeutics Provides Company Update Today
30.5.202313:00GLOBEPlus Therapeutics Announces Topline Results from Recurrent..
25.5.202313:00GLOBEPlus Therapeutics to Present at the 2023 Virtual June..
16.5.202313:00GLOBEPlus Therapeutics Regains Compliance with Nasdaq Listing..
12.5.202313:00GLOBEPlus Therapeutics to Present in EndBrainCancer Initiative..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock